Citations

Clear

1325 citation(s) found for "Mayo, Angela".

Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin
Kumar, Shaji , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | November 15, 2018 | Volume: 37 | Issue: 2 | Pages: 171-173

10.1200/jco.18.01398 | PMID 30433848 Get It

Myeloma in Elderly Patients: When Less Is More and More Is More
Rosko, Ashley , Mateos, María‐Victoria , Giralt, Sergio , Dispenzieri, Angela

Mayo Clinic

American Society of Clinical Oncology Educational Book | October 29, 2018 | Volume: No volume available | Issue: 37 | Pages: 575-585

10.1200/edbk_175171 | PMID 28561667 Get It

Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient’s functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.
P2‐651: A CONSENSUS AROUND GLOBAL RESEARCH PRIORITIES FOR COMMUNITY‐BASED CARE FROM A STRATEGIC CONVENING MODEL IN SALZBURG, AUSTRIA
Lunde, Angela , Johnston, Claiborne S., Roger, Véronique L. , Gordon, Kate , Nomidou, Aikaterini , Little, A. N., Agbaje, Babatunde, Mastery, Olivia, Hu, William T. , Gordon, Kate, Kayano, Ryoma

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_18 | Pages: No page available

10.1016/j.jalz.2018.06.1347 Get It

Utility and prognostic value of 18F‐FDG positron emission tomography‐computed tomography scans in patients with newly diagnosed multiple myeloma
Aljama, Mohammed A. , Sidiqi, M Hasib , Lacy, Martha Q. , Gertz, Morie A. , Dingli, David , Muchtar, Eli , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Gertz, Morie A , Fonder, Amie L, Gonsalves, Wilson , Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi Lisa, Leung, Nelson , Go, Ronald S , Rajkumar, S Vincent , Muchtar, E , Sidiqi, M Hasib , Dingli, David , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | September 8, 2018 | Volume: 93 | Issue: 12 | Pages: 1518-1523

10.1002/ajh.25279 | PMID 30194770 Get It

AbstractPositron emission tomography‐computed tomography (PET‐CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET‐CT within 60 days of a new diagnosis (before therapy commenced) to identify the nature and prognostic impact of PET‐CT abnormalities. Patients (N = 313) were seen from April 2005 through June 2017. Of the 234 patients (75%) with focal lesions (FLs), 182 (58%) had at least 3 FLs, 38 (12%) had EMD, and 204 (65%) had documented myelomatous lytic lesions. The median maximum standardized uptake value (SUVmax) for the entire cohort was 5.9 (range 1.5‐48.3). Presence of at least 3 FLs and EMD predicted inferior overall survival (OS); median OS was 57.8 months for patients with 3 or more FLs and 103.6 months for patients with fewer than 3 FLs (P = .003). The median OS was 45.5 and 71.8 months for patients with and without EMD, respectively (P = .004). No clear SUVmax cutoff was predictive of progression‐free survival or OS. PET‐CT is a valuable tool for assessing disease burden and could provide prognostic information about a contemporary cohort of patients with newly diagnosed myeloma who received treatment with novel agents.
Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.
Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Zeldenrust, Steven R., Lust, John A., Kyle, Robert A. , Kumar, Shaji , Sidana, Surbhi , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Gonsalves, Wilson I. , Leung, Nelson

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8062-8062

10.1200/jco.2016.34.15_suppl.8062 Get It

Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM).
Finnes, Heidi D. , Kumar, Shaji , LaPlant, Betsy, Lacy, Martha Q. , Merten, Julianna A., Bartoo, Gabriel , Kapoor, Prashant , Gertz, Morie A. , Buadi, Francis K. , Dispenzieri, Angela , McCullough, Kristen , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8058-8058

10.1200/jco.2016.34.15_suppl.8058 Get It

Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.
Tandon, Nidhi , Lacy, Martha Q. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Kumar, Shaji , Buadi, Francis K. , Leung, Nelson , Go, Ronald S. , Dingli, David , Gertz, Morie A. , Lin, Yi , Dispenzieri, Angela , Drake, Matthew T. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8053-8053

10.1200/jco.2016.34.15_suppl.8053 Get It

Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.
Bartley, Adam C. , Ashrani, Aneel A. , Hashmi, Shahrukh K. , Kapoor, Prashant , Kyle, Robert A. , Ravindran, Aishwarya , Gonsalves, Wilson I. , Marshall, Ariela L. , Siddiqui, Mustaqeem , Dispenzieri, Angela , Rajkumar, S. Vincent , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8035-8035

10.1200/jco.2016.34.15_suppl.8035 Get It

Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.
Kumar, Shaji , Lacy, Martha Q. , Zeldenrust, Steven R., Hayman, Suzanne R. , Kourelis, Taxiarchis , Lust, John A., Kapoor, Prashant , Kyle, Robert A. , Muchtar, Eli , Dispenzieri, Angela , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Chakraborty, Rajshekhar , Dingli, David , Lin, Yi , Go, Ronald S. , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8016-8016

10.1200/jco.2016.34.15_suppl.8016 Get It